mp-2

Myelopeptide-2 (MP-2) with the sequence Leu-Val-Val-Tyr-Pro-Trp is originally isolated from the supernatant of porcine bone marrow cell culture and is able to restore the mitogen responsiveness of human T lymphocytes inhibited by conditioned medium from H

Risvodetinib, a potent inhibitor of protein tyrosine kinases, specifically targets the synthesis of Abelson protein kinases (c-Abl1, c-Abl2, and c-kit).

Anti-Mouse IL-3 Antibody (MP2-8F8) is an IgG1 antibody inhibitor derived from rats that targets and inhibits mouse IL-3.

XMU-MP-2 is a potent and selective protease inhibitor with anticancer activity that inhibits the growth of oncogenic BRK-driven tumors in a mouse xenograft model.

MMP-2Inhibitor-4 (Compound 5g) is an MMP-2 inhibitor with an IC50 of 152.62 nM. It effectively reduces MMP-2 levels in K562 cell lines by stably binding to the active site of MMP-2 and exhibits strong anti-angiogenic effects in ACHN cell lines. MMP-2Inhibitor-4 shows potential for research in chronic myelogenous leukemia (CML).

The compound c-(2'FdAMP-2'FdIMP) (Compound 52) is a derivative of cAIMP and a cyclic dinucleotide (CDN). It acts as a STING agonist and significantly induces STING-dependent signaling pathways involving IRF and NF-κB. This compound is applicable in STING-based immunotherapy, including studies on cancer and infectious diseases.

MMP-2/9-IN-2 (Compound 6k) functions as an inhibitor of MMP-2 and MMP-9, with IC50 values of 29.27 μM and 24.87 μM, respectively. It exhibits selective toxicity against various human liver cancer cell lines and induces cell cycle arrest and apoptosis (apoptosis), significantly inhibiting cell migration and invasion. Additionally, MMP-2/9-IN-2 suppresses the phosphorylation of the STAT3 signaling pathway and demonstrates potent antitumor activity in a nude mouse xenograft model with HepG2 liver cancer cells.

MMP-2/MMP-9-IN-1 is a potent, highly selective, and orally bioavailable inhibitor of type IV collagenases [MMP-9 and MMP-2], exhibiting IC50 values of 0.24 μM for MMP-9 and 0.31 μM for MMP-2, which can be used to study cancer.

BMP-22 is an inhibitor of autotaxin (IC50 = 170 nM). It is selective for autotaxin over the phosphodiesterases NPP6 and NPP7 at 10 μM. BMP-22 (0.1-1,000 nM) inhibits autotaxin-mediated production of lysophosphatidic acid (LPA) from lysophosphatidylcholine in vitro in a concentration-dependent manner. It inhibits LPC-dependent MM1 cell invasion of a human umbilical vein endothelial cell (HUVEC) monolayer. BMP-22 (0.5 mg/kg per day) decreases the number of lung metastatic foci in a B16/F10 syngeneic mouse melanoma model of lung metastasis.

MMP-2/9-IN-1 (Compound 4a) is a potent dual inhibitor of MMP-2 (IC50: 56 nM) and MMP-9 (IC50: 38 nM), leading to DNA fragmentation.

AMP-224 is a fusion protein that targets PD-L2 and can specifically bind to PD-1T cells (long-term stimulated/exhausted T cells). It is applicable in research on colorectal cancer and solid tumors.

CMP-2-Aminoethylphosphonate is a type of nucleotide metabolite.

Ilomastat (GM6001) (GM6001, Galardin) is a broad spectrum matrix metalloprotease (MMP) inhibitor.

NLRP3/AIM2-IN-3 is a unique molecule that inhibits NLRP3 and AIM2 inflammasome activation in a species-specific manner. It has an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 is a potent inhibitor of NLRP3 and AIM2 inflammasome-dependent cell lysis with an IC50 value for cell lysis of 0.077 ± 0.008 μ M. NLRP3/AIM2-IN-3 inhibits LPS/nigericin NLRP3/AIM2-IN-3 inhibits LPS/nigericin-stimulated cell lysis in THP-1 macrophages with an IC50 value of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 interferes with the interaction of NLRP3 or AIM2 with the bridging protein ASC, inhibiting oligomerization of ASC.

Marimastat (BB2516) (BB-2516) is a potent, broad spectrum matrix metalloprotease (MMP) inhibitor. MMP-9 (IC50=3 nM), MMP-1 (IC50=5 nM), MMP-2 (IC50=6 nM), MMP-14 (IC50=9 nM)and MMP-7 (IC50=13 nM).

KP-457 is a specific inhibitor of a disintegrin-metalloproteinase 17 (ADAM17) and a TNFα converting enzyme TACE inhibitor that blocks the production of soluble TNF (sTNF).

UK-101 is a small molecule inhibitor and a selective inhibitor of the immunoproteasome β1i (LMP2) subunit (IC50=104 nM), with 144-fold and 10-fold selectivity over the β1c and β5 subunits, respectively. This compound can induce apoptosis, possesses antitumor activity, and can be used for prostate cancer-related research.

ND-322 HCl (ND 322 Hydrochloride) is a selective inhibitor of MT1-MMP and MMP2 and reduces in vitro melanoma cell growth, migration and invasion.

CP-544439 is an orally active and potent MMP-13 inhibitor that prevents diet-induced obesity and inhibits adipogenesis in 3T3-L1 preadipocytes in mice, and can be used for the study of obesity.

Sulfalene (SMP2), a long-acting sulfonamide antibiotic, is used for the therapy of chronic bronchitis, urinary tract infections, and malaria.

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

Efavirenz (DMP 266) is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor, acting as a Non-Nucleoside Reverse Transcriptase Inhibitor, Cytochrome P450 3A Inducer, Cytochrome P450 2B6 Inducer, Cytochrome P450 2C9 Inhibitor, Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 3A4 Inhibitor, classified as a Non-Nucleoside Analog.

Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.

Ethyl gallate (gallic acid ethyl ester) obviously decreases cell proliferation in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner, exhibits cytotoxicity in a dose-dependent manner. Ethyl gallate can inhibit the abilities of invasion of breast cancer in vitro by inhibiting the mRNA levels of MMP-9/MMP-2, phosphorylation of Akt and protein expression of NF-κB and inhibits hydrogen peroxide signaling, may represent an alternative class of vasopressors for use in septic shock. Also, Ethyl gallate suppresses proliferation and invasion in human breast cancer cells by modulating the PI3K/Akt pathway, which may contribute to inhibiting their downstream targets such as NF-κB p-65, Bcl-2/Bax, and mRNA levels of MMP-2 and MMP-9 in breast cancer cells, could be used as potential antioxidants with safe therapeutic application in cancer chemotherapy.